Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
8
|
pubmed:dateCreated |
1993-1-15
|
pubmed:abstractText |
The combined effects of the synthetic glucosaminylmuramyl dipeptide (GMDP) on the antitumor activity of chemically synthesized lipid A analogs, compound A-103 (glucosamine-4-phosphate with (R)-3-tetradecanoyloxytetradecanoyl group at the C-2 and C-3 positions), Escherichia coli-type lipid A (506), Salmonella typhimurium LT-2 lipopolysaccharide (LPS) against Meth A fibrosarcoma in mice were examined. Meth A fibrosarcoma cells (5 x 10(5) were inoculated intradermally into BALB/c mice on day 0, and compound A-103 and/or GMDP was administered intravenously (i.v.) on days 7 and 9. Two i.v. injections of A-103 (50 micrograms) alone or GMDP (10 micrograms) alone induced 42.8 or 51.8% inhibition of the rate of tumor growth, however, A-103 (100 micrograms) with GMDP (10 micrograms) exhibited a high 68.7% inhibition rate 19 days after tumor inoculation. The inhibition of the tumor growth rate by the combination A-103 (100 micrograms) or 506 (50 micrograms) with GMDP (10 micrograms) was stronger than that of A-103 or 506 with MDP (10 micrograms). The combination of LPS (1 or 10 micrograms) with GMDP (10 micrograms) exhibited a higher inhibition rate than that of LPS with MDP, and three or four tumor-free mice out of five mice were observed, suggesting that the combined effect of GMDP is more potent than that of MDP. With the addition of GMDP, A-103 did not enhance the production of tumor necrosis factor (TNF) on the basis of L929 cell lysis.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Acetylmuramyl-Alanyl-Isoglutamine,
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Lipid A,
http://linkedlifedata.com/resource/pubmed/chemical/Lipopolysaccharides,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/glucosaminylmuramyl-2-alanine-D-isog...
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0192-0561
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
14
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1415-20
|
pubmed:dateRevised |
2006-5-17
|
pubmed:meshHeading |
pubmed-meshheading:1464473-Acetylmuramyl-Alanyl-Isoglutamine,
pubmed-meshheading:1464473-Adjuvants, Immunologic,
pubmed-meshheading:1464473-Animals,
pubmed-meshheading:1464473-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:1464473-Fibrosarcoma,
pubmed-meshheading:1464473-Lipid A,
pubmed-meshheading:1464473-Lipopolysaccharides,
pubmed-meshheading:1464473-Male,
pubmed-meshheading:1464473-Mice,
pubmed-meshheading:1464473-Mice, Inbred BALB C,
pubmed-meshheading:1464473-Mice, Inbred C3H,
pubmed-meshheading:1464473-Tumor Necrosis Factor-alpha
|
pubmed:year |
1992
|
pubmed:articleTitle |
Combined effects of synthetic lipid A analogs or bacterial lipopolysaccharide with glucosaminylmuramyl dipeptide on antitumor activity against Meth A fibrosarcoma in mice.
|
pubmed:affiliation |
Department of Microbiology, University of Shizuoka, School of Pharmaceutical Sciences, Japan.
|
pubmed:publicationType |
Journal Article
|